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Plasma proteome is widely used in studying changes occurring in human body during disease or other disturbances.
Immunological methods are commonly used in such studies. In recent years, mass spectrometry has gained popularity in
high-throughput analysis of plasma proteins. In this study, we tested whether mass spectrometry and iTRAQ-based protein
quantiﬁcationmightbeusedinproteomicanalysisofhumanplasmaduringlivertransplantationsurgerytocharacterizechangesin
proteinabundancesoccurringduringearlygraftreperfusion.Wesampledbloodfromsystemiccirculationaswellasbloodentering
and exiting theliver. After immunodepletion of sixhigh-abundant plasmaproteins,trypsin digestion,iTRAQlabeling, andcation-
exchangefractionation,thepeptideswereanalyzedbyreversephasenano-LC-MS/MS.Intotal,72proteinswereidentiﬁedofwhich
31 could be quantiﬁed in all patient specimens collected. Of these 31 proteins, ten, mostly medium-to-high abundance plasma
proteins with a concentration range of 50–2000mg/L, displayed relative abundance change of more than 10%. The changes in
protein abundance observed in this study allow further research on the role of several proteins in ischemia-reperfusion injury
during liver transplantation and possibly in other surgery.
1.Introduction
Blood plasma is one of the most complex biological ﬂuids
in humans. It contains hundreds of physiological circu-
latory proteins and hundreds to thousands of condition-
speciﬁc proteins that change in concentration in response
to pathophysiological changes in the body [1]. This richness
of proteins and its accessibility makes plasma one of the
most commonly used sources for medical diagnostics [2–
4]. Currently used routine immunodiagnostic tests are able
to identify and quantify numerous plasma biomarkers with
great precision and sensitivity. The problem with modern
immunodiagnostic methods is that they are based on
antibody interactions with the proteins being investigated,
requiring a separate test for each biomarker, thus increasing
the workload and costs in medical healthcare. To overcome
the limitations of single ELISA assay, several chip-based
antibody microarray methods have been developed [5–7]. In
antibody microarrays the antibodies are attached to the sur-
face of the assay chip and the sample is ﬂushed over the chip
allowing the proteins to bind to the antibodies on the chip.
After washes the bound proteins can be detected with either
direct labeling [8] or indirect sandwich type immunoassays
[9]. The main beneﬁt of antibody microarrays is the sensi-
tivity and precision of traditional antibody assays combined
withthespeedandeﬃciencyofanalyzingnumerousproteins
simultaneously. The disadvantage is the requirement for
speciﬁc antibodies targeted to the desired proteins or against
each posttranslationally modiﬁed version of the protein.
In addition, the dynamic range of antibody microarrays is
generally similar to normal ELISA-type assays, ranging three
to four orders of magnitude [6, 10, 11] complicating the2 Journal of Biomedicine and Biotechnology
analysis of complex, high dynamic range samples such as
plasma. Consequently, the current antibody arrays are most
suitable for targeted analysis of disease or condition-speciﬁc
biomarkers [7, 12–14] rather than examining changes in the
whole proteome or discovering novel biomarkers.
Advances in the ﬁeld of mass spectrometry (MS) have
enabled an alternative way of investigating cellular and
plasma protein biomarkers [15–17]. Current MS machinery
and bioinformatics software are rapidly approaching the
sensitivity and dynamic range limits of immunodiagnostic
tests [18, 19]. The main beneﬁt of the MS-based assay is
the ability to characterize tens to hundreds of proteins
simultaneously [20] without the need to target any speciﬁc
posttranslational modiﬁcation, subproteome, or disease.
Further, parallel analysis of several proteins in a single MS
run greatly reduces the time and costs of diagnostic analyses.
The drawback on using plasma in MS-based assays is the
high dynamic range of protein abundances [3]. Albumin,
the most abundant protein in plasma, constitutes ca. 60%
of the entire amount of proteins in plasma at approximate
concentration of 50mg/mL. On the other hand, cytokines
are found in plasma at the level of picograms per milliliter or
lower. Such variability in protein abundances is a problem
for modern mass spectrometers with a dynamic range of
103–104 [21]. In this study we examined the applicability
of iTRAQ peptide labeling technology [22] to characterize
relative changes in the levels of several plasma proteins
during liver transplantation (Figure 1).
The success of liver transplantation is signiﬁcantly inﬂu-
enced by both preservation and reperfusion injury. During
procurement, liver is disconnected from circulation, result-
ing in interrupted oxygen supply to cells. Ischemia induces
several physiological eﬀects such as activation of apopto-
sis and necrosis pathways [23]. Upon graft implantation,
the cells suﬀer from reperfusion injury. Reactive oxygen
species are generated after the sudden increase in cellular
oxygen levels leading to DNA, plasma membrane, and
protein damage [24].Further,inﬂammation and coagulation
cascades become activated damaging both the graft and
other end-organs. Characterization of protein abundance
changes during liver transplantation could be extremely
helpful in patient prognosis and care. In this pilot study
we characterized several plasma proteins that change in
abundance during graft reperfusion in liver transplantation
using iTRAQ peptide labeling technology.
Blood samples were drawn simultaneously from portal
and hepatic veins and from radial artery. Following immun-
odepletion of the six high-abundant humanplasma proteins,
the plasma proteome was digested to peptides with trypsin.
The digests were then labeled with iTRAQ 8plex mass
tags. The iTRAQ technology is based on small amine-
reactive isobaric mass tags that can be attached to the N-
terminus and lysine residues of digested peptides. The tag
consists of a reporter ion used for quantiﬁcation and a
balancer group balancing the reporter masses of each iTRAQ
tag to equal mass. During collision-induced fragmentation
within the mass spectrometer the peptide bound mass tag
is fragmented, along with the peptide backbone, to produce
a balancer group and a reporter ion of known mass (113,
114, 115, 116, 117, 118, 119, and 121 daltons in iTRAQ 8plex
system). Each reporter ion produces a distinct MS fragment
where the intensity of the reporter ion fragment corresponds
to the amount of the peptide. The relative abundances of the
peptides, and ultimately proteins, which are derived from
diﬀerent iTRAQ labeling pools (i.e., diﬀerent samples), can
be deduced from these spectra.
Samples were fractionated by means of strong cation-
exchange and reverse phase chromatography and ﬁnally
analyzed by quadrupole time-of-ﬂight mass spectrometry.
Protein identiﬁcation and quantiﬁcation was performed
using the Mascot search engine. We were able to identify 72
diﬀerent proteins and to quantify 31 of those proteins in all
patient specimens.
2.MaterialsandMethods
2.1. Patients and Sampling. Three male patients undergoing
livertransplantationsurgeryforprimarysclerosingcholangi-
tis (PSC) in the transplantation and liver surgery clinic of the
surgical hospital participated in this study (Table 1). Patients
with PSC were recruited to ensure similar surgical technique
and comparable cold ischemia and anhepatic times and peri-
operative bleeding. The patients were transplanted within a
time period of two months.
The study was approved by the Ethics Committee of the
Department of Surgery, Hospital District of Helsinki and
Uusimaa (DNr. 33/13/03/02/08). All grafts were obtained
from brain-dead donors and were preserved with University
of Wisconsin solution. The classic surgical technique of
transplantation was used without bypass or piggyback. In
brief, the patient’s native liver is removed after clamping of
supra- and infrahepatic inferior caval vein. Then the portal
vein and hepatic artery are clamped. The suprahepatic caval
anastomosis is completed ﬁrst. Just before completion of
portal anastomosis, the liver is ﬂushed via the portal vein
with 1000mL of Ringer’s solution with the suprahepatic
caval vein clamped, followed by rinse with 400mL of portal
venous blood. After graft rinsing, the suprahepatic caval and
portal veins are declamped, followed by completion of the
infrahepatic caval anastomosis and declamping. Finally, the
hepatic arterial anastomosis is completed.
Three separate 10mL blood specimens were taken from
each patient during early graft reperfusion. A sample repre-
senting blood ﬂow from the liver was drawn from hep-
atic vein during graft ﬂushing with portal blood before
permanent connection to circulation. Simultaneously, a
sample representing blood entering the liver was drawn from
portal vein. To monitor changes in systemic circulation, an
additional sample was drawn from radial artery. Samples
from hepatic and portal veins were drawn by puncture
directlyfromthevesselwhereasthesamplefromradialartery
was drawn from an indwelling arterial cannula. All samples
were drawn into sterile syringes and transferred immediately
to sodium citrate anticoagulated tubes (Vacutainer Systems
Europe, Becton Dickinson, Plymouth, UK) and placed on
ice until further processing. Within 30 minutes, plasma was
separated by centrifugation at 2000g for 10 minutes at +4◦C
and aliquotted to 150μL fractions. The aliquots were thenJournal of Biomedicine and Biotechnology 3
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Figure 1: General workﬂow for patient sampling, iTRAQ labeling, and protein quantiﬁcation. All patient samples are depleted and trypsin
digested separately. Each sample is then labeled with a diﬀerent iTRAQ mass tag whereafter the samples are pooled. The pooled samples are
fractionated with strong cation exchange and reverse-phase chromatography and analyzed by quadrupole time-of-ﬂight mass spectrometry.
The resulting Mascot peptide fragmentation spectra (upper spectra image) provide the peptide sequence and the low mass end (highlighted
in lower spectra) shows the iTRAQ reporter ion region used for quantiﬁcation.4 Journal of Biomedicine and Biotechnology
Table 1: Patient characteristics.
Patient 1 Patient 2 Patient 3
P a t i e n tw e i g h t( k g ) 6 8 7 4 6 2
Patient age (yrs) 35 39 47
Liver cold ischemia time (min) 273 295 279
Anhepatic time (min) 51 52 57
Weight of the transplanted liver
(grams) 1400 750 1100
Total bleeding in the operation
(liters) 1.8 2.3 3.6
stored at −80◦C until analysis. Samples from each patient
were analyzed at the same time, approximately 6 months
after sampling. The entire protocol for each patient was
performed twice from depletion to MS analysis.
2.2. Plasma Depletion. To pellet the precipitated material,
450μL of plasma were thawed on ice and centrifuged at
16100g at +4◦C for 5 minutes. The supernatant was diluted
1:5 with Agilent Multiple Aﬃnity Removal Buﬀer A and
proteinase inhibitor was added to the samples (complete
EDTA free mini, Roche Diagnostics GmbH, Mannheim,
Germany). The samples were ﬁltered with 0.22μm syringe
ﬁlters (low protein binding Durapore, Millipore Corpora-
tion, Billerica, MA). Protein concentrations measurements
were done from all samples using BCA protein concentra-
tion measurement kit (Pierce, Rockford, IL). In order to
maintain the original concentration ratios throughout the
processing of the samples, the volumes were kept equal in
all samples, 455μL of diluted plasma from each sample were
diluted to 2mL with Agilent Buﬀer A. Six high-abundant
plasma proteins, including albumin, IgG, IgA, transferrin,
haptoglobin, and antitrypsin, were depleted using Agilent
Multiple Aﬃnity Removal LC Column-Human 6 (Agilent
Technologies, Palo Alto, CA) using Waters 666 pump and
600S controller HPLC system coupled to Waters 2487
Dual wavelength absorbance detector (Waters Corporation,
Milford, MA). The injection volume was 200μL, 1.75mL
of ﬂow thru fraction containing low abundance proteins
was collected. Injection and collection was performed
three times to monitor the reproducibility of the deple-
tion (representative chromatograms of repeatability and
sample-to-sample comparison are shown in Supplemental
File 4 in supplementary Material available online at doi:
10.1155/2011/248613). A control sample was prepared by
pooling and then aliquotting the arterial, hepatic, and portal
vein samples from one patient. The control sample was
used in iTRAQ quantiﬁcation as a benchmark to which all
three patient samples were compared in order to acquire the
quantiﬁcationvalues.Allsampleswerethenstoredat −80◦C.
2.3. Protein Precipitation, Digestion, and iTRAQ Labeling.
Portal, hepatic, and arterial blood samples from two patients
were analyzed simultaneously with the control sample.
150μL of the low abundance protein fraction, containing
an average protein mass of 51.75μg in arterial sample,
51.05μg in portal sample, and 40.4μg in hepatic sample,
was precipitated by adding 100% trichloroacetic acid to a
ﬁnal concentration of 25% (v/v) and incubated on ice for 30
minutes with periodic vortexing. Precipitated proteins were
pelleted by centrifugation (16100g, +4◦C, 5 minutes) using
a table top centrifuge. The protein pellet was washed once
with 500μLo f−20◦C acetone with 0.1M hydrochloric acid
and centrifugated (16100g, +4◦C, 5 minutes), and the wash
was repeated using −20◦Ca c e t o n e .
Digestion was performed by the iTRAQ peptide labeling
protocol by AB Sciex (Concord, Canada). All used buﬀers
were from iTRAQ Reagent 8plex Buﬀer Kit from AB Sciex.
First,theproteinsamplesweredissolvedinto50μLofiTRA Q
dissolution buﬀer. Two microliters of iTRAQ denaturant
were added to the samples and mixed vigorously to solubilize
the protein pellet. Then 2μL of reducing reagent were
added and samples were incubated at +60◦Cf o r1h o u r .
After reduction, 1μL of cysteine blocking reagent was added
followed by incubation at room temperature for 10 minutes.
Two micrograms of trypsin (Promega sequencing grade
modiﬁed trypsin, Promega, Madison, WI) were added to the
samples, which were then incubated at +37◦C for approx-
imately 16 hours.
iTRAQ reagents were dissolved in 50μLo fi s o p r o p a n o l
and transferred to the digested peptide samples. The labeling
reaction was performed at room temperature for 2 hours
before quenching by 10μLo f1Ma m m o n i u mb i c a r b o n a t e .
Quenching was allowed to progress at room temperature for
30 minutes. After labeling, the samples were pooled into a
new sample tube (the full iTRAQ labeling scheme is given in
Supplemental File 4).
2 . 4 .P e p t i d eF r a c t i o n a t i o na n dM a s sS p e c t r o m e t r y . To reduce
the complexity of peptide samples for MS, a fractionation
step was performed with a cation-exchange cartridge system
(AB Sciex). The cartridge was washed and conditioned
according to the Manufacturer’s instructions. The pooled
sample was evaporated to below 30μL, diluted to 1mL of
cation-exchange load buﬀer and pH was adjusted to 2.5–
3.5 with HCl. The sample was slowly injected into the
cartridge and washed with 1mL of cation-exchange load
buﬀer. Elution of peptides was performed by increasing the
concentration of KCl. Eleven 500μL elution fractions were
collected(5mM,10mM,15mM,25mM,35mM,50mM,
75mM, 100mM, 150mM, 200mM, and 350mM KCl in
10mM KH2HPO4,p H= 3, with 25% acetonitrile). All
fractions were dried in a SpeedVac vacuum concentrator
(ThermoSavant, Holbrook, NY) and solubilized to 100μLo f
MS phase A buﬀer (5% acetonitrile with 0.1% formic acid).
Fractions were stored at −20◦C until mass spectrometric
analysis.
On-line reverse phase separation was performed using
Waters Symmetry300, C18, 5μm NanoEase Trap Column
coupled to an LC Packings-Dionex Acclaim PepMap C18
column, 75μm × 250mm (LC Packings/Dionex, Amster-
dam, The Netherlands) on a Waters-Micromass nanoLC
CapLC (passive stream-split) coupled to a Q-TOF Ultima
Global mass spectrometer. Eluent A contained 0.1% formicJournal of Biomedicine and Biotechnology 5
acid in 5% acetonitrile, eluent B 0.1% formic acid in 95%
acetonitrile. The ﬂow rate during the LC-run was set to
300–400nL/minute depending on the amount of organic
solvent, with a gradient ranging from 95% to 5% of eluent
A. MS data was acquired for 90 minutes in positive ion
modebydata-dependentacquisitioncollectingtheprecursor
MS and six MSMS spectra during one duty cycle. The
threshold for switching to MSMS was set to ten counts per
second for each individual ion and 5 counts per second
for switching back to MS scan. The scan time was 2.4
seconds with a 0.1 second interscan delay. The scan range
for MS scan was set to 300–2000m/z and 50–2500 for
MSMS. No lock-mass correction was used (Exact Waters-
Micromass nanoLC CapLC and Q-TOF Ultima Global mass
spectrometer settings and an example chromatogram of MS
run are shown in Supplemental File 4).
2.5. Protein Identiﬁcation and iTRAQ Quantiﬁcation. Each
M Sr u nw a sp e r f o r m e dt w i c et og a t h e rm o r ed a t aa n dt o
compensate for the stochastic nature of the data-dependent
acquisition. The peak lists were calculated using Mascot
Distiller Software (version 2.3.1.0, Matrix Science, London,
UK) and the data from each KCl elution fraction was
merged. Peptides were identiﬁed with Mascot search engine
(version 2.2.04, Matrix Science) against SwissProt database
(version 57.7) with Homo sapiens as the speciﬁed organism.
The parameters for search were trypsin digested peptides
with maximum of two missed cleavages, iTRAQ-8plex on
lysine and N-terminus as well as methylthio-cysteine as
ﬁxed modiﬁcations, and oxidation of methionine as variable
modiﬁcation. Default Mascot iTRAQ correction factors
were used to compensate for the iTRAQ reagent isotope
impurities. Peptide tolerances for the search were ±0.2 Da
for parent and ±0.1 Da for fragment ions resulting in false
discovery rate of less than 1.4% when searched against false
decoy database. The signiﬁcance threshold for peptides was
set to “Identity” and probability value of 0.05. For peptide
identiﬁcation, a Mascot peptide score of more than 20 was
required and “Require bold red” designation was used for
protein identiﬁcation.
After peptide identiﬁcation, an exclusion list was con-
structed from the identiﬁed peptides. This exclusion list
was used in subsequent identical MS run to search for
unidentiﬁed peptides. The resulting peak lists were again
merged and searched. A second exclusion list was created
from these results and combined with the ﬁrst list. The
fractions were then similarly analyzed with MS for the third
time. The beneﬁt of using exclusion lists is clearly illustrated
in Figure 2 representing the total distinct peptides that were
identiﬁed in ﬁrst iTRAQ experiment. The ﬁrst exclusion
MS run identiﬁed 97 and the second 38 additional novel
peptides.Ontheaverage,theﬁrstexclusionrunincreasedthe
distinct peptide count by 28% and the second run by 10%.
All peak lists, from the no-exclusion to two exclusion runs
were ﬁnally combined and searched with the same search
parameters.
Protein identiﬁcation and quantiﬁcation was performed
with Mascot search engine using MudPIT scoring for protein
identiﬁcation. Normalization was done using summed pep-
tide intensities and automatic outlier removal. This corrects
for the possible dilution eﬀect of rinsing the graft with
Ringer solution before ﬂushing with portal blood. This
normalization step is based on the assumption that the
overall plasma protein concentration does not change in the
liver. Protein ratios were calculated as median ratio of each
patient sample to control sample with at least three peptides
requiredforquantiﬁcation,(fullcombinedMascotresultsare
g i v e ni nS u p p l e m e n t a lF i l e s1 – 3 ) .
The quantiﬁcation results were copied to Microsoft
Oﬃce Excel (Microsoft Corporation, Redmond, WA) and
diﬀerences between samples were calculated as percent
changes. Change across the hepatic circulation (portal to he-
patic venous change) was calculated as hepatic vein quantiﬁ-
cation value subtracted by the portal vein value and divided
by the original hepatic vein value. Similarly, change from
systemic circulation to portal venous blood was calculated
as portal vein quantiﬁcation values subtracted from arterial
value and divided by the original portal value. To calculate
the change between arterial and hepatic venous samples,
the hepatic vein values were subtracted from arterial value
and then divided by hepatic vein value. Finally the resulting
values were multiplied by 100 to gain percentage changes.
All quantiﬁcation values of patient samples and repeat
runswerethenaveraged.Duetothesmallnumberofpatients
and quality of the data, a signiﬁcance threshold of 10% was
used to ﬁlter the results.
3. Results
The blood samples were obtained from patients undergoing
liver transplantation surgery during the early phase of
reperfusion.Samplesweredrawnfromtheportalvein(blood
entering the liver), hepatic vein (blood exiting the liver), and
the radial artery (systemic circulation).
After sampling blood was centrifuged to yield plasma.
The protein concentrations were measured before high
abundance plasma protein depletion. Generally the portal
venous and systemic arterial samples had equal concen-
trations, 76.4mg/mL in portal venous and 74.5mg/mL in
arterial blood, while the hepatic venous samples had a
markedly lower concentration, an average of 53.6mg/mL.
The dilution is probably due to surgical procedures as the
liver is ﬁrst rinsed with Ringer solution before ﬂushing
with portal blood and subsequent sampling of this eﬄuent
blood from hepatic vein. To reduce the complexity of the
samples by removing the highly abundant albumin and
ﬁve other high-abundant proteins (IgG, IgA, transferrin,
haptoglobin, and antitrypsin), a small aliquot of each sample
was subjected to Agilent Multiaﬃnity Removal column. This
depletion step reduced the protein content of the samples by
65 to 75%.
After depletion, trypsin digestion, iTRAQ labeling, ex-
tensive peptide fractionation, and mass spectrometer runs,
the data ﬁles of each patient and repeat runs were com-
bined. This overall list was then searched against Swiss-Prot
human database and 72 proteins were identiﬁed with good6 Journal of Biomedicine and Biotechnology
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Figure 2: The beneﬁt of using multiple exclusion MS runs. Venn diagram of the peptides identiﬁed in the ﬁrst iTRAQ experiment. The
no-exclusion run identiﬁed 324 distinct peptides. Of these 128 were identiﬁed in the ﬁrst exclusion run together with 74 novel peptides. The
second exclusion run produced 38 additional novel peptides that had not been identiﬁed in the no-exclusion or in the ﬁrst exclusion MS
runs.
conﬁdence (Table 2. A complete list of all identiﬁcations and
quantiﬁcation is found in Supplemental Files 1–3).
Most of the identiﬁed proteins (53 of 72) are found on
top of the 150 most abundant proteins in plasma (HUPO
Plasma Proteome Project 3020 conﬁrmed identiﬁcations
[25]). This demonstrates the limitations in sensitivity and
dynamic range of the mass spectrometer used in this study.
Of the 72 identiﬁed proteins, 31 could be quantiﬁed in all
patient specimens and repeat runs (Figure 3).
As the identiﬁed proteins belong to the medium-to-high
abundance plasma protein category and major changes in
protein abundance are improbable, we decided to consider
signiﬁcant only those changes where the average change of
all MS runs was more than 10%.
For changes within the liver from portal to hepatic
venous blood, eight proteins changed more than 10%.
Five of these were reduced in concentration: histidine-
rich glycoprotein (HRG, Swiss-Prot:P04196), antithrombin-
III (SERPINC, Swiss-Prot:P01008), ﬁbrinogen alpha chain
(FGA, Swiss-Prot:P02671), apolipoprotein E (APOE Swiss-
Prot:P02649),andbeta-2-glycoprotein1(APOHSwiss-Prot:
P02749)) and three had increased across the liver: alpha-
1-acid glycoprotein 1 (ORM1 Swiss-Prot: P02763), inter-
alpha-trypsin inhibitor heavy chain H4 (ITIH4 Swiss-Prot:
Q14624), and alpha-2-macroglobulin (A2M Swiss-Prot:
P01023). The diﬀerences in plasma proteome in systemic
arterial to hepatic venous sample were similar to the portal
to hepatic venous change: HRG, SERPINC, and FGA had
lower and ORM1, ITIH4, and A2M higher concentrations
within the liver. Additionally two other proteins, serum
paraoxonase/arylesterase 1 (PON1 Swiss-Prot: P27169) and
angiotensinogen (AGT Swiss-Prot: P01019) increased in
concentration. The changes observed in the systemic arterial
to portal venous blood were not as extensive as portal to
hepatic vein changes. Only two proteins, PON1 and AGT,
increased more than 10%.
4. Discussion
Using plasma depletion, mass spectrometry based protein
identiﬁcation and iTRAQ labeling of peptides, we were able
to identify 72 diﬀerent, mostly medium to high abundance
plasma proteins in blood samples taken from patients
undergoing liver transplantation. This bias of medium-to-
high proteins is not unexpected as the depletion column
removesonlysixofthemostabundantproteins.Additionally
the sensitivity of the used mass spectrometer limits the
dynamic detection limit to the high concentration plasma
proteins. For this reason major changes in the detected
proteins are unlikely. Of the 72 identiﬁed proteins 31 were
quantiﬁed in all patients. Of these 31 proteins, ten proteins
changed more than the 10% conﬁdence limit. We then
compared the changes in protein abundances from portal
venous to hepatic venous blood, systemic arterial to hepatic
venous blood, and systemic arterial to portal venous blood.
The changes in portal to hepatic venous blood and systemic
arterial to hepatic venous blood were quite similar. The
observed changes in arterial to portal blood are quite small
as only two proteins were shown to diﬀer.
4.1. Sample Characteristics. We used several methods to
reduce the inherent complexity of the plasma sample. Six
high-abundant proteins were removed from plasma using
the Agilent Multiple Aﬃnity Removal system reducingJournal of Biomedicine and Biotechnology 7
Table 2: All identiﬁed proteins.
Protein
hit no.
Swiss-Prot
accession
number
Protein description Protein
score
Protein
mass (Da)
Protein
sequence
coverage
Number of
unique
peptides
1 P01023 Alpha-2-macroglobulin A2M 23708 190553 35.8 46
2 P01024 Complement C3 C3 21127 221709 49.9 68
3 P02671 Fibrinogen alpha chain F 9678 108299 29.6 26
4 P04114 Apolipoprotein B-100 AP 8935 624146 14.9 55
5 P02647 Apolipoprotein A-I AP 8930 37756 65.9 24
6 P02652 Apolipoprotein A-II AP 6461 14514 44 6
7 P01011 Alpha-1-antichymotrypsin SERPINA3 5929 55834 45.4 16
8 P02675 Fibrinogen beta chain F 2192 67148 36.9 17
9 P02774 Vitamin D-binding protein 2072 66618 16.7 9
10 P05155 Plasma protease C1 inhibitor SERPIN 1533 64246 22.6 10
11 P02679 Fibrinogen gamma chain F 1472 62126 25.6 10
12 P02766 Transthyretin TTR 1306 18615 38.8 6
13 P00450 Ceruloplasmin CP 1254 142509 16.7 12
14 P0C0L4 Complement C4-A C4A 1224 216378 10 12
15 P06727 Apolipoprotein A-IV AP 1041 54193 37.4 13
16 P01008 Antithrombin-III SERPINC1 989 64129 30.6 10
17 P04217 Alpha-1B-glycoprotein A1B 971 57889 28.1 12
18 Q14624 Inter-alpha-trypsin inhibitor heavy chain H4 ITIH4 920 116070 18 11
19 P04196 Histidine-rich glycoprotein HR 874 66538 8 3
20 P08697 Alpha-2-antiplasmin SERPINF2 872 60615 8.1 2
21 P01871 Ig mu chain C region I 837 56272 21.2 8
22 P01834 Ig kappa chain C region I 739 14340 17 1
23 P00751 Complement factor B CFB 650 101906 12.8 12
24 P10909 Clusterin CLU 650 61587 8.9 4
25 P02649 Apolipoprotein E AP 543 40391 40.4 10
26 P01019 Angiotensinogen A 537 59813 15.1 5
27 P19823 Inter-alpha-trypsin inhibitor heavy chain H2 ITIH2 407 126474 7.6 5
28 P01042 Kininogen-1KN 375 87731 11.2 8
29 P27169 Serum paraoxonase/arylesterase 1 P 332 46113 16.1 4
30 P04003 C4b-binding protein alpha chain C4BPA 299 77637 2 1
31 P25311 Zinc-alpha-2-glycoprotein AZ 297 40239 12.4 2
32 P02656 Apolipoprotein C-III AP 295 12975 16.2 1
33 P68871 Hemoglobin subunit beta HBB 241 19639 36.7 4
34 P04264 Keratin, type II cytoskeletal 1 KRT1 239 74821 1.9 1
35 P51884 Lumican LUM 237 46314 11.8 2
36 P02760 Protein AMBP AMBP 219 44754 3.4 1
37 P02790 Hemopexin HPX 206 58336 10.2 6
38 P19827 Inter-alpha-trypsin inhibitor heavy chain H1 ITIH1 198 115927 5.8 4
39 P04004 Vitronectin VTN 194 60659 5.6 2
40 P02763 Alpha-1-acid glycoprotein 1 167 28060 19.4 5
41 P00734 Prothrombin F2 149 79118 6.9 3
42 P08603 Complement factor H CFH 123 163645 2.5 3
43 P02765 Alpha-2-HS-glycoprotein AHS 121 44471 6.5 3
44 P02655 Apolipoprotein C-II AP 113 13406 32.7 3
45 P01842 Ig lambda chain C regions I 110 13967 26.8 28 Journal of Biomedicine and Biotechnology
Table 2: Continued.
Protein
hit no.
Swiss-Prot
accession
number
Protein description Protein
score
Protein
mass (Da)
Protein
sequence
coverage
Number of
unique
peptides
46 P02751 Fibronectin FN1 103 286474 2 4
47 P01031 Complement C5 C5 88 224691 1.6 2
48 P02735 Serum amyloid A protein SAA1 84 15349 11.5 1
49 P10643 Complement component C7 C7 73 108363 1.1 1
50 P36955 Pigment epithelium-derived factor SERPINF1 65 54831 7.4 2
51 P43652 Afamin AFM 63 84843 7.2 3
52 Q9NP78 ATP-binding cassette subfamily B member 9 ABCB9 56 92635 0.9 1
53 P06681 Complement C2 C2 54 94470 2.4 2
54 P01876 Ig alpha-1 chain C region I 49 41890 8.2 3
55 P00747 Plasminogen PL 49 105720 5.4 5
56 P02747 Complement C1q subcomponent subunit C C1QC 46 29712 3.7 1
57 P02743 Serum amyloid P-component APCS 46 29326 2.7 1
58 P13645 Keratin, type I cytoskeletal 10 KRT10 45 66119 3.9 2
59 P02753 Retinol-binding protein 4 RBP4 43 26646 5 1
60 P00915 Carbonic anhydrase 1 CA1 42 34632 4.6 1
61 P02749 Beta-2-glycoprotein 1 AP 39 47703 2.6 1
62 P05452 Tetranectin CLEC3B 38 27724 5.9 1
63 P15169 Carboxypeptidase N catalytic chain CPN1 35 57729 4.1 2
64 P02452 Collagen alpha-1(I) chain C 34 156470 1 2
66 P02746 Complement C1q subcomponent subunit B C1QB 32 31310 15 2
67 P07357 Complement component C8 alpha chain C8A 32 75160 3.1 1
65 Q5XKE5 Keratin, type II cytoskeletal 79 KRT79 32 66900 2.2 1
69 P04278 Sex hormone-binding globulin SHB 31 47706 6 1
68 P05546 Heparin cofactor 2 SERPIND1 31 67377 1.4 1
71 P35858 Insulin-like growth factor-binding protein complex
acid labile chain I 30 69340 2.6 1
70 P06396 Gelsolin 30 99638 2.2 1
73 Q5T8A7 Protein KIAA0649 KIAA0649 29 150089 1 1
72 Q2WGJ9 Fer-1-like protein 6 FER1L6 29 259655 0.3 1
the protein content of the samples by more than 65%.
The depletion allows the identiﬁcation of more proteins
in the sample [26] by reducing the dynamic range and
by increasing the amount of medium-to-low abundance
proteins that can be labeled and injected to MS. Even though
depletion reduces the complexity and dynamic range of the
analysis, it also removes those plasma proteins that bind
to albumin, immunoglobulins, or other high abundance
proteins [27]. This carrier eﬀe c tm a yc a u s es o m ed i ﬀerences
in quantiﬁcation results especially with low abundance
proteins. This issue was not considered signiﬁcant in this
study as the quantiﬁed proteins belong to the medium-to-
high abundance plasma protein category.
After trypsin digestion and iTRAQ labeling the peptides
were puriﬁed and fractionated oﬄine using strong cation
exchange cartridge followed by online separation with
reverse phase chromatography coupled to MS. Such two-
dimensional fractionation setup is extremely important in
iTRAQ-based peptide quantiﬁcation [28]. First, the com-
plexity is reduced allowing a more detailed MS analysis as
the mass spectrometer can only analyze a certain amount
of ions during one duty cycle. Second, the prefractionation
decreases the chances of false peptide quantiﬁcation due
to simultaneous fragmentation of coeluting peptides with
equal mass that originate from diﬀerent proteins. Third, two
fractionation steps allow for a greater amount of sample to
be loaded onto the column, thus increasing the chance of
detecting lower abundanceproteins. The drawback of several
fractionationstepsisthecostintimeandpossiblesampleloss
during fractionation.
Despiteitsprovenreliability,iTRAQ-basedproteinquan-
tiﬁcation has some inherent problems that may aﬀect the
results.Diﬀerentproteinisoforms,variousglycosylation,and
other posttranslational modiﬁcations may cause discrepancy
in peptide-based quantiﬁcation. These issues are fundamen-
tal in plasma proteomics, but they are not discussed in
here. It should be noted that the physiological status of the
recipient and donor as well as medication and care before
and during surgery may also aﬀect general liver functions.Journal of Biomedicine and Biotechnology 9
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Figure 3: All quantiﬁed proteins and percent changes. The Mascot quantiﬁcation results from all patients and MS repeat runs were averaged
andthepercentchangevalueswerecalculated.Allchangesabove10%wereconsideredsigniﬁcant.TheproteinsarerepresentedasUniProtKB
protein and gene names and accessions.
Protein degradation during sample collection, handling,
and storage is of major concern when quantifying plasma
proteins [29–31]. Protein half-lives in normal circulation are
controlled by production by liver or other tissues, clearance
through various organs, or degradation by circulatory pro-
teases [32]. After sampling, the degradation is continued by
p l a s m ap r o t e a s e sa sw e l la su n s p e c i ﬁ cp r o t e o l y s i so fl a b i l e
proteins through physicochemical fragmentation. Therefore,
the speed of sample handling, length of storage and temper-
ature, and as simultaneous sample analysis as possible, are
crucial factors in quantifying plasma proteome samples [29].
Althoughbloodsampleswereimmediatelykeptat+4◦Cafter
sampling, long-term stored at −80◦C[ 29, 33], and kept on
ice with proteinase inhibitors added prior to depletion, we
cannot rule out the eﬀect of nonspeciﬁc protein degradation
during sample handling or storage on the ﬁnal results.
However, in our opinion the eﬀe c to fs u c hd e g r a d a t i o ni s
moderate as our experiment identiﬁed mainly medium-to-
high abundance proteins. It has been shown that sample
storage temperature and time do not have a profound eﬀect
on the low-molecular-weight proteome [33] or the high-
abundant proteins [29].
Further, we assume that while each protein species has a
unique half-life or degradation time, it is constant between
samples (e.g., albumin in arterial sample degrades at the
same rate as in portal or hepatic venous samples). Even
though the proteins are constantly degraded, aﬀecting the
absolute abundances of proteins in samples, the relative
abundances of each protein species between the samples
remains more or less the same. As all three samples from one
patient were analyzed always at the same time using the same
protocol, the eﬀect of protein degradation on relative iTRAQ
quantiﬁcation is likely minor.
W eo b s e r v e dam a j o rr e d u c t i o ni no v e r a l lp r o t e i nc o n -
centrations in hepatic venous samples as compared to those
taken from radial artery and portal vein. This signiﬁcant
reduction of almost 30% was considered to be caused by
rinsing the graft with Ringer solution before rinsing with
portal blood and subsequent sampling. This dilution eﬀect
is compensated by the normalization step in Mascot iTRAQ
quantiﬁcation method.
4.2. Changes in the Hepatic Circulation. As the hepatic
venous samples contain the ﬁrst blood rinsed through
the transplanted liver, the changes in protein abundances
between portal and hepatic venous blood reﬂect the severity
of reperfusion injury. At this point, hepatic arterial blood
ﬂow is not yet reconstructed. Therefore the hepatic venous
protein content is not inﬂuenced by the systemic arterial
proteome. In this study ﬁve proteins were found to decrease
across the hepatic circulation. These were histidine-rich gly-
coprotein (HRG), antithrombin-III (SERPINC1), ﬁbrinogen
alpha chain (FGA), apolipoprotein E (APOE), and beta-2-
glycoprotein 1 (APOH).
The most notable reduction of nearly 30% in the con-
centration was observed with HRG. HRG is a glycosylated
plasma protein with histidine and proline rich regions [34].
Produced by the liver, HRG is found in plasma at a relatively10 Journal of Biomedicine and Biotechnology
high concentration of 100mg/L and at a much lower con-
centration in platelets [35]. Although the main function of
HRG is not entirely clear, it is suggested to participate in
immunoregulation, metal homeostasis, and blood coagula-
tion [36]. HRG interacts with plasminogen, heparin, and
thrombospondin[37–39].Itsroleincoagulationmayexplain
the reduction in HRG levels in liver transplantation as the
coagulation system is activated in the ischemia-reperfusion
injury. Alternatively, HRG may be retained in the liver in
immunoregulative functions as the graft is recognized as
foreign material by the innate immune system.
Additionally, the levels of three other proteins related to
coagulation decreased across the hepatic circulation, imply-
ing protein consumption within the graft. Antithrombin-
III [40] is an important regulator of coagulation [41]. It
inhibits thrombin and several other serine proteases of the
clotting cascade [42]. Fibrin, on the other hand, is the
main component of ﬁbrin clots. It is formed by cleavage of
ﬁbrinopeptides from ﬁbrinogen alpha and beta chains [43].
Another potential coagulation inhibitory protein is beta-2-
glycoprotein-1orapolipoproteinH(APOH).APOHbinding
to the exposed phospholipids of the damaged tissues may
inhibit activation of the coagulation cascade [44].
Hepatic consumption of these four proteins indicates
that blood coagulation is activated immediately during graft
reperfusion. Innate immune system recognizes the postis-
chemic liver tissue and beta-2-glycoprotein attaches to the
surface of the broken cells. Reperfusion rapidly initiates
blood coagulation, leading to ﬁbrinogen conversion to ﬁbrin
and ﬁbrin clots, whereas SERPINC1 is consumed in the
liver to inhibit excessive thrombin formation. Further, HRG
i sr e t a i n e di nt h el i v e rt op r o m o t ec o a g u l a t i o no rt oe x e r t
immunoregulative functions. This proposed cascade leads to
the observed uptake of these proteins into the liver.
The levels of Apolipoprotein E (APOE), a major compo-
nent of chylomicrons and other low-density lipoprotein
particles, were lower in the hepatic venous samples when
compared to those from the portal vein. APOE is produced
in a variety of tissues, including the liver. APOE mediates
functions of the chylomicron internationalization process,
in which the lipids and cholesterol of chylomicrons are
transported from intestines to tissues. APOE also mediates
the removal of chylomicron remnants in hepatocytes [45].
This detected APOE uptake reﬂects the chylomicron and
APOE clearance from the blood into the liver.
Three proteins were found to increase in concentration
across the hepatic circulation. These include alpha-1-acid
glycoprotein (ORM1), inter-alpha-trypsin inhibitor heavy
chain H4 (ITIH4), and alpha-2-macroglobulin (A2M). All
three are high-abundant plasma proteins produced by the
liver,ITHI4,andORM1almostexclusively.A2Misaprotease
inhibitor that inhibits a wide range of proteases including
thrombin, plasmin, and kallikrein [46]. ITIH4 and ORM1
both function in acute-phase reactions [47, 48].
The proﬁle of changes in HRG, SERPINC1, FGA,
ORM1, ITIH4, and A2M levels was similar when systemic
arterial samples were compared to either hepatic or portal
venoussamples.Thissuggeststhatthemajorchangesinthese
proteins indeed take place in the liver and not in other parts
of the body.
5. Conclusions
Using protein depletion and LC-MS/MS we have analyzed
the very early ischemia-reperfusion changes in plasma pro-
teome during liver transplantation surgery. Despite the
sensitivity limit imposed by the used mass spectrometer and
analysis methods we were able to characterize diﬀerences
in several plasma proteins. Major changes were observed in
proteins involved in coagulation, especially in histidine-rich
glycoprotein. Further studies are needed to validate these
results. Nevertheless, our data demonstrates that MS-based
protein identiﬁcation and quantiﬁcation is a feasible option
when examining the eﬀects of major surgery or other organ-
related shock to plasma proteome.
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